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Abstract Evidence-based clinical guidelines ensure best practice protocols are available in health
care. There is a widespread use of human papillomavirus deoxyribonucleic acid (HPV-
DNA) tests in Brazil, regardless of the lack of ofﬁcial guidelines. On behalf of the
Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC,
in the Portuguese acronym), a team of reviewers searched for published evidence and
developed a set of recommendations for the use of HPV-DNA tests in cervical cancer
screening in Brazil. The product of this process was debated and consensus was sought
by the participants. One concern of the authors was the inclusion of these tests in the
assessment of women with cytologic atypia and women treated for cervical intra-
epithelial neoplasia (CIN). Testing for HPV is recommended in an organized screening
scenario to identify women with precursor lesions or asymptomatic cervical cancer
older than 30 years of age, and it can be performed every 5 years. It also has value after
the cytology showing atypical squamous cells of undetermined signiﬁcance (ASC-US) or
low-grade squamous intraepithelial lesions (LSILs) as a triage test for colposcopy, in the
investigation of other cytological alterations when no abnormal ﬁndings are observed
at colposcopy, seeking to exclude disease, or, further, after treatment of high-grade
cervical intraepithelial neoplasia, to rule out residual disease.
Resumo O uso de diretrizes clínicas baseadas em evidências visa assegurar as melhores práticas na
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The present article is a result of the review and update
process of the Brazilian Guidelines for Cervical Cancer
Screening,1 published in 2016. Human papillomavirus deox-
yribonucleic acid (HPV-DNA) tests had already been widely
used in Brazil for years, without speciﬁc national guidelines,
and these recommendations aimed to ﬁll this gap.
Thus, theworkgroup that revised and updated the current
Brazilian guidelines prepared the present document on
behalf of the Brazilian Association for the Lower Genital
Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese
acronym). This document does not represent the position of
the Brazilian Ministry of Health on the use of DNA-HPV
detection tests, and it should be emphasized that this text
does not replace the existing recommendations, which are
based on technologieswidely recognized and available to the
Brazilian population.
The aim of these recommendations is to guide practi-
tioners working in scenarios in where the test is available, so
they can use it according to the best practice and in the light
of the best evidence.
The process of building these recommendations was
described in the Brazilian Guidelines for Cervical Cancer
Screening - 2nd edition, revised, expanded and updated.1
Technical Considerations
By “HPV-DNA test,” we mean any test for the detection of
oncogenic HPV-DNA in biological specimens obtained by a
cervical smear or brushing. The detection of non-oncogenic
HPV types is not clinically relevant in this setting.
Generally, the use of HPV-DNA tests in cervical cancer
screening is beneﬁcial because it is more sensitive, identify-
ing more womenwith precursor lesions and cancer than the
conventional Pap smear. On the other hand, because of its
lower speciﬁcity, more women may be unnecessarily re-
ferred for colposcopy, which leads to an increase in costs and
unwanted morbidity.
One advantage of HPV-DNA tests following an abnormal
Pap smear is their high negative predictive value. When
oncogenic HPV-DNA is undetectable, the occurrence of pre-
cursor lesions or cervical cancer is very unlikely.
Methods
In summary, from February 2013 to August 2014, almost 40
experts got together to update the previously published
recommendations2 based on the best available evidence.
Among these experts were prominent gynecologists with
known experience in the subject, as well as representatives
of institutions involved in cervical cancer screening and the
follow-up of abnormal screening tests, who share the au-
thorship of this paper. The remaining participants of the
revision and consensus process are listed in the Acknowl-
edgments. The review leaders were selected by a panel of
specialists leaded by the ABPTGIC. Each review leader invited
other specialists from other parts of the country, considering
their work in the speciﬁc area of interest. Each review group
reviewed one main topic, searching for the best evidence in
original articles or secondary information sources, submit-
ting their summary and updated recommendations to the
whole group. The result of the work of each group was
discussed in videoconferences and, at the end of this process,
the ﬁnal text was discussed in a special meeting in Rio de
Janeiro.
The following text presents, in each topic, evidence that
supports the use of the HPV-DNA tests in each individual
scenario. The evidence from the literature was classiﬁed as
high, moderate or low, according to the risk of bias (►Table 1).
The summary of evidences is followed by speciﬁc recom-
mendations that resulted in the experts’ consensus. Each
recommendation is followed by a capital letter in parentheses,
meaning its strength, based on the degree of certainty from
the best scientiﬁc evidence and judgment of the partici-
pants (►Table 2). In ►Table 3 we list the most relevant
recommendations.
humano (DNA-HPV) vem crescendo e se disseminando sem que existam recomendações
deusono cenário brasileiro. EmnomedaAssociaçãoBrasileira dePatologia doTratoGenital
Inferior e Colposcopia (ABPTGIC), grupos de revisores pesquisaram evidências e formula-
ram recomendações para o uso dos testes de DNA-HPV no rastreamento do câncer do colo
do útero, no seguimento de mulheres com atipias citológicas, e após tratamento de
neoplasia intraepitelial cervical (NIC). O produto desse processo foi debatido e foi buscado
consenso entre participantes. Os testes de DNA-HPV são recomendados num cenário de
rastreamento organizado para identiﬁcação demulheres portadoras de lesões precursoras
ou câncer assintomático com mais de 30 anos e podem ser realizados a cada 5 anos.
Também têm valor após a citologia mostrando células escamosas atípicas de signiﬁcado
indeterminado (ASC-US) ou lesão intraepitelial escamosadebaixo grau (LSIL) como teste de
triagem para colposcopia, na investigação de outras alterações citológicas quando não são
observados achados anormais à colposcopia, buscando excluir doença, ou, ainda, no
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HPV-DNA Test Use in Cervical Cancer Screening
The occurrence of false-negative and unsatisfactory cytology
tests prompted the development of new technologies that
improve screening quality.4 In addition, the evidence of a
causal relationship between oncogenic HPV infection and
cervical cancer and its precursor lesions led to the develop-
ment of HPV-DNA detection techniques to prevent and
identify these lesions.5
There is currently scientiﬁc evidence supporting HPV-DNA
tests as the primary screening method for women aged
30yearsorolder. Screening forHPV-DNAhasahighsensitivity,
and anticipates the diagnosis of cervical intraepithelial neo-
plasia (CIN) II and III evenwhen thescreening isperformed ina
5-year interval. This technique is better than regular cervical
cytology in the diagnosis of glandular lesions (adenocarcino-
ma) (evidence level: high).6 Staff training is fast, laboratory
Table 1 Level of certainty
Certainty Level Description
High The available evidence usually includes consistent results from well-designed and well-conducted studies
among the representative populations to which they apply. These studies assess the effects of the
preventive practice on health outcomes. This conclusion is therefore unlikely to be strongly affected
by the results of future studies.
Moderate The available evidence is sufﬁcient to establish the effects of the preventive practice on health
outcomes, but conﬁdence is limited by factors such as:
• The number, size or quality of the individual studies
• Inconsistency in the ﬁndings across individual studies
• Limited generalizability of the ﬁndings to the routine practice
• Lack of consistency in the chain of evidence
As more information becomes available, the magnitude or direction of the observed effect may change,
and this change may be large enough to alter the conclusion.
Low The available evidence is insufﬁcient to assess effects on health outcomes. The evidence is
insufﬁcient because of:
• The limited number or size of the studies
• Important ﬂaws in the studies’ designs or methods
• Inconsistency in the ﬁndings across individual studies
• Gaps in the chain of evidence
• Findings not generalizable to the routine practice
• Lack of information on important health outcomes
More information can allow estimates of the effects on health outcomes.
The United States Preventive Services Task Force (USPSTF) attributes a level of certainty based on the general nature of the evidence available to
assess the net beneﬁt of a preventive practice.3
Table 2 Strength of recommendation
Grade Definition Recommendations for practice
A The practice is recommended. There is high cer-
tainty that the net beneﬁt is substantial.
Offer or provide the practice.
B The practice is recommended. There is high cer-
tainty that the net beneﬁt is moderate or there is
moderate certainty that the net beneﬁt is moder-
ate to substantial.
Offer or provide the practice.
C The practice is not routinely recommended. There
may be considerations that support the practice at
an individual level. There is at least moderate
certainty that the net beneﬁt is small.
Offer or provide this service for selected patients
depending on individual circumstances.
D The practice is not recommended. There is mod-
erate or high certainty that the practice has no net
beneﬁt, or that the damages outweigh the
beneﬁts.
Discourage the use of this practice.
I The current evidence is insufﬁcient to assess the
balance between its beneﬁts and harms. The evi-
dence is lacking, of poor quality, or conﬂicting, and
the balance of beneﬁts and harms cannot be
determined.
Read the introductory text containing evidence
obtained in the literature review that supports this
recommendation. If the practice is offered, the
patients should understand that there is uncer-
tainty in the balance between beneﬁts and harms.
The United States Preventive Services Task Force (USPSTF) deﬁnes certainty as the “likelihood that the USPSTF’s assessment of the net beneﬁt of a
preventive practice is correct.” The net beneﬁt is deﬁned as the beneﬁt minus the practice injury when implemented in a general population.2
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results are reproducible, and it qualiﬁes for self-sample HPV-
DNA-based screening (evidence level: high).7
The main limitation of HPV-DNA-based tests is their low
speciﬁcity (positive results when there is no lesion – a com-
mon ﬁnding inwomen under 30 years of age) (evidence level:
high).8 To avoid an excessive number of women unnecessarily
referred to colposcopy because they were screened with a
positive HPV result, triage methods are necessary. One option
is the cytology triage of HPV-DNA-positive cases, referring
only women who tested positive for HPV-DNA and whose
cytology test was abnormal (evidence level: high).9 This
strategy has proven to be more sensitive and to have the
same speciﬁcity as cytology alone in a Swedish randomized
clinical trial, which was part of the national population-based
screening program (evidence level: high).10
Screening for HPV-DNA has a greater operational advan-
tage if performed using a sample that would also allow a
cytology triage, and this is the case of the liquid medium.
Therefore, if the HPV-DNA test is positive, the cytology test
can be performed in the same sample, and a new sample
collection is not necessary, thus saving time and resources.
Human papillomavirus types 16 and 18 (genotyping) in
women with a positive HPV-DNA test and a negative cytolo-
gy have shown favorable results for the selection of women
with a higher probability of having CIN II or higher type (CIN
II þ). Prospective studies with a large number of women
support the immediate referral of patients with positive
HPV-DNA types 16 and 18 to colposcopy, regardless of the
use of cytology as triage (evidence level: high).11–13
In summary, screening withHPV-DNA-based testsmay be
advantageous inwomen aged 30 years or older, followed by a
triage with cytology, provided that only those with cytologi-
cal atypia are referred for colposcopy. This is true for an
organized screening scenario, that is, one in which there is a
control of who should be screened at the recommended time
intervals. There are only a fewmunicipalities with organized
cervical cancer screening programs in Brazil. There is no
suitable control of the women who carry out their screening
or howoften they do it. Thus, there are no tools to ensure that
the interval between screening tests will be effectively
widened with the adoption of an HPV-DNA test, nor that
women missed by this screening program will be identiﬁed.
Furthermore, in most Brazilian municipalities, the cost-
effectiveness improvement of HPV-DNA testing is not war-
ranted. Given this background, the use of this technology in
each and every municipality of Brazil can only be recom-
mended once their screening program is organized and
operational.
Recommendations
Testing based on HPV-DNA as an alternative to cytology in
cervical cancer screening should be performed every 5 years
in women aged 30 years or older, and may be extended up to
when the patients are 64 years of age (B). Testing for HPV-
DNA is unacceptable before the age of 30 (D). When an HPV-
DNA test is positive for oncogenic types, a cytology exam
should be performed, preferably using the same sample,
since no further sampling would be necessary. Therefore,
the recommended medium for HPV-DNA test collection is
the same as for liquid-based cytology (B).
If an HPV-DNA test is positive for oncogenic types and the
cytology shows any atypia (ASC-US or worse), the woman
should be referred for colposcopy (A). Instead, if the cytology
is negative, thewoman should repeat the HPV-DNA test after
12 months (A). If the HPV-DNA result remains positive for
oncogenic types, the woman should be referred for colpos-
copy (A). If the sample is negative for oncogenic HPV on the
ﬁrst or second sampling opportunity after a negative cytolo-
gy, a newcytology exammust be performed after three years
(A). If HPV-DNA genotyping is available and is positive for
HPV types 16 or 18, the woman should be directly referred
for colposcopy, bypassing the cytology test (A). If an HPV-
DNA test (with or without genotyping) is negative, it should
be repeated in 5 years (A). Any therapeutic procedure
Table 3 Most relevant recommendations for the use of the HPV-DNA test in cervical cancer screening and after an abnormal
cytology
The HPV-DNA test can be the primary screening method as an alternative to cytology in women aged 30 years or older.
When negative, the test should be repeated every 5 years.
When the HPV-DNA test is positive for oncogenic HPV, triage with cytology is recommended. If genotyping is available
and if it is positive for HPV types 16 or 18, the woman may be referred for colposcopy.
Women aged 30 years or older with ASC-US can perform the HPV-DNA test as an alternative to a new cytology after 6 months.
Women 30 years of age or older with LSIL can perform the HPV-DNA test to select those who should be referred for
colposcopy.
In women with ASC-H or HSIL and normal colposcopy, a negative HPV-DNA test will virtually rule out precursor lesions or
invasive disease.
In women with AGC or AIS and normal colposcopy, a negative HPV-DNA test means a low probability of cervical disease,
demanding investigation of the endometrium and other pelvic organs.
The HPV-DNA test may be used at follow-up after the treatment of CIN II/III and AIS to exclude residual or recurrent lesions,
and it is recommended between 6 and 12 months after the treatment.
Abbreviations:ASC-H, atypical squamouscells, cannot excludehigh-grade squamous intraepithelial lesion; ASC-US, atypical squamous cells of undetermined
signiﬁcance; AGC, atypical glandular cells; AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia;HPV, humanpapillomavirus;HPV-DNA,human
papillomavirus deoxyribonucleic acid; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.
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performed because of a positive HPV-DNA test is unaccept-
able (D). Women between the ages of 25 and 29 should keep
performing cytology tests (A). Women aged 65 years or older
who tested negative forHPV-DNAmaydiscontinue screening
(B). ►Fig. 1 summarizes the recommendations for the use of
HPV-DNA tests in cervical cancer screening.
Use of HPV-DNATests in the Follow-up ofWomen with
Abnormal Cytology Results
Atypical Squamous Cells
Atypical Squamous Cells of Undetermined Signiﬁcance (ASC-
US), Possibly Non-neoplastic
The cytology diagnosis of atypical squamous cells of unde-
termined signiﬁcance (ASC-US) does notmean, inmost cases,
the presence of a precursor lesion or cancer. However,
identifying whichwomenwith this diagnosis are more likely
to have one of these lesions has led to several screening
recommendations for colposcopy referral.
Asmentioned in the Brazilian Guidelines for Cervical Cancer
Screening,1 there is a similarity among management recom-
mendations for woman with ASC-US in France,14 the
United Kingdom,15 and Australia and New Zealand.16 In these
countries, a repeat cytology test is recommended after 6 to
12 months. The American Society for Colposcopy and Cervical
Pathology (ASCCP) states thatusing theoncogenicHPV-DNAtest
for women aged over 25 with ASC-US cytology is preferable to
cytology. This sameguideline states that this test is acceptable in
21- to 24-year-old women with ASC-US, but repeat cytology is
preferable in this age range.17 The guidelines published in
Korea18 and Argentina19 follow ASCCP recommendations and
Fig. 1 Recommendations for HPV-DNA testing in cervical cancer screening in women aged 30 to 64 years.
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endorse the use of oncogenic HPV-DNA testing in women with
ASC-US cytology.
Recommendations
Womenwith ASC-US cytology can perform theHPV-DNA test
alternatively to a new cytology test within 6 months. If the
test is positive for oncogenic types, the woman should be
referred for colposcopy (A).
The HPV-DNA test can also be used to outline the follow-
up of women with ASC-US cytology aged 30 years or older
after a negative colposcopy. If the test is positive, the woman
should be followed in the primary care unit in the same way
as the others. She should undergo a new cytology test every
6months (for women aged 30 years or more) or annually (for
younger women) (I) until 2 consecutive negative test results
are achieved, then she should return to triennial cytological
screening, unless a different cytology result occurs (A). If the
HPV-DNA test is negative for oncogenic types, this woman
may return to triennial screening (A).
Atypical Squamous Cells, Cannot Exclude High Squamous
Grade Intraepithelial Lesion (ASC-H)
Differently from the diagnosis of ASC-US, in the presence of
atypical squamous cells, cannot exclude high squamous
grade intraepithelial lesion (ASC-H), the probability of a
precursor lesion or cancer is signiﬁcantly higher. Of all
current recommendations, the most favored is referral to
colposcopy.
However, in many cases, colposcopy cannot ensure there
is no lesion, and a negative oncogenic HPV-DNA test virtually
ensures its absence (evidence level: moderate).20
Recommendations
When available, the HPV-DNA test may also be used in
women with an ASC-H cytology who have a type-III
transformation zone (TZ) and no abnormal colposcopy
ﬁndings (B). If there is no oncogenic HPV, this woman
may return to triennial cytology screening (I). If there are
abnormal ﬁndings, this woman should continue to undergo
the investigation of the endocervical canal as recom-
mended by the Brazilian Guidelines for Cervical Cancer
Screening (I). If the presence of a precursor or invasive
lesion is not proven, the HPV-DNA test may also be used at
the follow-up. In this case, it should be performed within
6 months of the initial cytology test (A). If there is no
oncogenic HPV, this woman can go back to triennial
screening (A). If oncogenic HPV is present, this woman
should be referred for colposcopy to ensure there are no
precursor lesions (I).
In postmenopausal women with an ASC-H cytology test,
the HPV-DNA test may also be used, avoiding topical estro-
gens before a new colposcopy, as indicated in the Brazilian
Guidelines (I). If there is no oncogenic HPV, this woman may
return to triennial cytological screening (I). If positive for
oncogenic HPV, she should be followed as recommended in
the Brazilian Guidelines for Cervical Cancer Screening: con-
tinuation of the investigation, preferably with estrogen
preparation (I).
Atypical Glandular Cells (AGC)
Atypical Glandular Cells of Undetermined Signiﬁcance,
Possibly Non-neoplastic or Atypical Glandular Cells in Which
High-grade Intraepithelial Lesions Cannot Be Ruled Out
Atypical glandular cells are another challenge. The preva-
lence of precursor lesions and invasive disease in women
with this cytological diagnosis is higher than in womenwith
ASC-US. In addition, most glandular lesions are in the endo-
cervical canal, which is often a colposcopic challenge, with
less speciﬁc colposcopic ﬁndings than those of squamous
lesions.
Considering the limitations of cytology and colposcopy in
such situations, the HPV-DNA test may provide additional
information to the investigation. The presence of oncogenic
HPV-DNA also showed associationwith invasive or precursor
glandular disease (evidence level: high).21 The probability
that an intraepithelial lesion may reach 40% when oncogenic
HPV types are present, compared with 4% when absent,
points to a possible use of this test in the investigation of
these women (evidence level: high).22
Recommendations
In women with an AGC cytology, and in situations in which
the colposcopy cannot ensure the absence of glandular
disease, a negative oncogenic HPV-DNA test will virtually
rule out precursor or malignant disease of the cervix (A).
Low-grade Squamous Intraepithelial Lesion (LSIL)
This cytology result implies a low probability of cancer or a
precursor lesion. In order to identifywomen at a greater riskof
developing these diseases and to deﬁne the need to refer them
for colposcopy, the use of HPV-DNA testswas proposed. In this
situation, HPV-DNA tests have a signiﬁcantly higher sensitivi-
ty, but signiﬁcantly lower speciﬁcity, when compared with
repeat cytology (evidence level: high).23 The low speciﬁcity of
HPV-DNA tests is due to the high HPV prevalence in women
with LSIL (76.9%) (evidence level: high),24which would imply
the referral of most women for colposcopy, compromising the
cost-effectiveness strategy. However, a positive HPV-DNA test
is determined by the prevalence of HPV infection, which in
turn is age-dependent. More recent studies have shown that
severalHPV-DNAtests have increased speciﬁcitywith increas-
ing age, in addition to high sensitivity, for the detection of CIN
II þ in women with LSIL (evidence level: high).25,26 Scientiﬁc
evidence suggests that HPV-DNA tests may be useful for the
triage of older womenwith LSIL. However, because of the lack
of stratiﬁed data, we don’t have enough evidence to recom-
mend the best moment to use it in this situation (evidence
level: high).27
Ameta-analysis of studies on the performance of HPV-DNA
test as a triage for the colposcopyof womenwith LSIL cytology
published in 2013 concluded that these tests may have a
greater ability to detect cases of NIC II þ. However, their use
should be weighed against the costs of the testing and the
colposcopy, in addition to the adherence to follow-up. Further-
more, they point out that DNA-HPV tests are certainly useless
in young women with LSIL, that more studies are needed to
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deﬁne their usefulness in the triage of older women (in the US
it is recommended for postmenopausal women), and that
higher cut-off points might be used to consider the test posi-
tive (evidence level: high).22
In the follow-up after colposcopy, if there are no abnormal
ﬁndings, or when the result is compatible with CIN I or a less
severe type, the sensitivity of the biannual cytology control
and the 12-month HPV-DNA test for CIN IIþ detection was
similar (89% and 92% respectively). However, the referral
rates for newcolposcopywere different (64% for cytology and
55% for HPV-DNA), pointing to a higher cost-effectiveness of
the HPV-DNA test (evidence level: high).26
Recommendations
Where HPV-DNA testing is available, it may be used in
women with LSIL cytology who are aged 30 years or older
for referral for colposcopy. If the HPV-DNA test is negative for
oncogenic types, the woman should return to triennial
cytology screening (I). If the HPV-DNA test is positive for
oncogenic types, the woman should be referred for colpos-
copy (I). In addition, after the ﬁrst colposcopy, in the follow-
up of the women with no abnormal ﬁndings or after the
histology diagnosis of CIN I, a 12-month HPV-DNA test may
be used (A) as an option. When oncogenic types are present,
the follow-up should be continued as aforementioned (A).
Negative cases should go back to the triennial cytology
screening routine (A).
High-grade Squamous Intraepithelial Lesion (HSIL)
The use of HPV-DNA tests is of no value for the colposcopy
referral of women after this cytology result. However, in
view of the high prevalence of oncogenic HPV types in
precursor lesions (evidence level: high),20 it can be useful
in situations inwhich the colposcopy cannot rule out disease.
Recommendations
In cases of high-grade squamous intraepithelial lesion (HSIL)
cytology, the HPV-DNA test, when available, may be used
only if there are normal or low-grade colposcopy ﬁndings. If
no oncogenic types are present, precursor or invasive disease
is virtually excluded, and the woman can return to triennial
cytology screening (A).
Adenocarcinoma in situ (AIS) and Invasive
Adenocarcinoma
These cytology results are a challenge for colposcopy. These
lesionsareusually located inside theendocervical canal andare
noteasily recognized, evenbyexperts. Occasionally, thedisease
may come from the endometrium or other pelvic organs.
As a result, there usually are no abnormal ﬁndings at the
colposcopy, and that requires an excisional diagnostic pro-
cedure, as well as investigation of the endometrium and
other pelvic organs in women aged 35 years or older, or
below that age if there is any abnormal bleeding.1
A negative oncogenic HPV-DNA test may be useful in
identifying women at a higher risk of having endometrial
disease, especially those over 50 years of age (evidence level:
moderate).28
Recommendations
Where available, HPV testing may be used in the initial
investigation of women with a cytology result of adenocarci-
noma in situ (AIS) or invasive adenocarcinoma. If negative, this
will mean a lower probability of having cervical disease, and
that will endorse the evaluationof the endometriumaswell as
of other pelvic organs inwomen aged 35 years or older and in
those with abnormal bleeding under 35 years of age (I).
Use of the HPV-DNA Test in the Follow-up of Women
Treated for Cervical Cancer Precursor Lesions
After Treatment of CIN II/III
Long-term follow-up studies indicate that women treated for
CIN II/III are at a higher risk of developing cervical cancer for at
least10years,andperhapsupto20yearsafter treatment,when
comparedwith the general population (evidence level: high).29
The ideal follow-up for the detection of residual or recur-
rent disease appears to be cytology associated with colposco-
py, but current data suggests that the HPV-DNA test identiﬁes
disease earlier, with greater sensitivity and speciﬁcity, than
the cytology follow-up (evidence level: moderate).30
Several studies have reported the elimination or persis-
tence of HPV infections after the treatment of high-grade
squamous intraepithelial cervical lesions. These reports vary,
and they sometimes show conﬂicting results. One study
reported that outof 49women treatedwith large loopexcision
of the transformation zone (LLETZ), only 6 (12.2%) persisted
with viral infection 3 months after the treatment (evidence
level:moderate).28Another study identiﬁed that at 31months
of follow-upafter a high-grade lesion treatment, theHPV-DNA
test was still positive in 19.6% of the patients, and no longer
detectable in 80.4% of the women (evidence level: moder-
ate).31 Another study showed that 94% of women with a
positive HPV-DNA test before treatment had cleared the
infection in 12 months (evidence level: moderate).32
Brazilian studies showed that most patients undergoing
excisional treatment for high-grade lesions were negative for
HPV-DNA six months after the procedure (evidence level:
moderate).33
Recommendations
The HPV-DNA test may be used for follow-up after NIC II/III
treatment to exclude residual or recurrent lesions. In this
case, it should be performed between 6 and 12 months after
the treatment (A). If cleared from oncogenic types, the
woman may return to triennial cytological screening (A).
After Treatment of Adenocarcinoma in situ
The HPV-DNA test can also be useful after a conservative
treatment for AIS (when the uterus is maintained) because, if
negative, it indicates that the patients have a lower risk of
persistence and relapse (evidence level: moderate).34
Recommendations
The HPV-DNA test may be used at follow-up after a conser-
vative AIS treatment (when the uterus is maintained) to
exclude residual or recurrent lesion. In this case, it should be
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performed 6 to 12 months after the treatment (A). If the
oncogenic HPV-DNA test is negative, the woman may return
to triennial cytological screening (A).
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